Table 2. Meta-analysis of the effect size for predictive factors of resistance to intravenous immunoglobulin therapy in Kawasaki disease.
| Variable | No. of studies | Type | ES | 95% CI | Heterogeneity | |
|---|---|---|---|---|---|---|
| P value | I2 | |||||
| WBC count (/mm3) | 12 | Fixed | 0.121 | 0.02-0.222 | 0.331 | 11.619 |
| PMN (%) | 10 | Random | 0.698 | 0.469-0.926 | 0.001 | 68.829 |
| Platelet count (×103/mm3) | 10 | Fixed | -0.176 | -0.282 to -0.070 | 0.716 | <0.0001 |
| ESR (mm/hr) | 7 | Random | 0.150 | -0.056-0.355 | 0.088 | 45.459 |
| CRP (mg/dL) | 12 | Random | 0.375 | 0.086-0.663 | <0.001 | 83.543 |
| Pro-BNP (pg/mL) | 5 | Random | 0.561 | 0.261-0.861 | 0.125 | 44.481 |
| Sodium (meq/L) | 10 | Random | -0.604 | -0.839 to -0.370 | <0.001 | 70.149 |
| Total bilirubin (mg/dL) | 8 | Random | 0.859 | 0.582-1.136 | <0.001 | 75.014 |
| AST (IU/L) | 10 | Random | 0.503 | 0.313-0.693 | 0.022 | 53.575 |
| ALT (IU/L) | 10 | Random | 0.436 | 0.275-0.597 | 0.115 | 36.728 |
| Albumin (g/dL) | 12 | Random | -0.427 | -0.657 to -0.198 | <0.001 | 73.424 |
ES, effect size (point estimate); CI, confidence interval; I2, I-squared statistic (measure of heterogeneity); WBC, white blood cell; Fixed, fixed-effects analysis; PMN, polymorphonuclear leukocyte; Random, random-effects analysis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Pro-BNP, pro-brain natriuretic peptide; AST, aspartate aminotransferase; ALT, alanine aminotransferase.